Agios Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2024 was $1,663.20 Mil.
During the past 12 months, Agios Pharmaceuticals's average Total Assets Growth Rate was 380.40% per year.
During the past 3 years, the average Total Assets Growth Rate was 22.60% per year.
During the past 5 years, the average Total Assets Growth Rate was 8.00% per year.
During the past 10 years, the average Total Assets Growth Rate was 16.60% per year.
During the past 13 years, Agios Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 125.10%. The lowest was -17.00%. And the median was 22.60%.
Agios Pharmaceuticals Total Assets Historical Data
The historical data trend for Agios Pharmaceuticals's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Agios Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agios Pharmaceuticals (NAS:AGIO) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Agios Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Agios Pharmaceuticals Total Assets Related Terms
Thank you for viewing the detailed overview of Agios Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AGIO has been successfully added to your 